{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:04:44Z","timestamp":1789736684994,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Institute of Heart Diseases, Wroclaw Medical University, Poland.","award":["SUBZ.A460.23.055"],"award-info":[{"award-number":["SUBZ.A460.23.055"]}]},{"name":"Institute of Heart Diseases, Wroclaw Medical University, Poland.","award":["SUBZ.A460.23.055"],"award-info":[{"award-number":["SUBZ.A460.23.055"]}]},{"name":"Institute of Heart Diseases, Wroclaw Medical University, Poland.","award":["SUBZ.A460.23.055"],"award-info":[{"award-number":["SUBZ.A460.23.055"]}]},{"name":"Institute of Heart Diseases, Wroclaw Medical University, Poland.","award":["SUBZ.A460.23.055"],"award-info":[{"award-number":["SUBZ.A460.23.055"]}]},{"name":"Institute of Heart Diseases, Wroclaw Medical University, Poland.","award":["SUBZ.A460.23.055"],"award-info":[{"award-number":["SUBZ.A460.23.055"]}]},{"name":"Institute of Heart Diseases, Wroclaw Medical University, Poland.","award":["SUBZ.A460.23.055"],"award-info":[{"award-number":["SUBZ.A460.23.055"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The decongestion ability in response to diuretic treatment plays a crucial role in the treatment of acute heart failure. This effectiveness is evaluated through the assessment of sodium concentration and urine volume, which are also treatment goals themselves. However, the bidirectional interconnection between these factors remains not fully understood. The objective of this study is to provide mechanistic insights into the correlation between spot urine sodium concentrations (UNa\n                    <jats:sup>+<\/jats:sup>\n                    ) and urine dilution. This aims to better understand of the decongestive abilities in acute heart failure (AHF). The study was single-center, prospective, conducted on a group of 50 AHF patients. Each participant received a standardized furosemide dose of 1\u00a0mg per kg of body weight. Hourly diuresis was measured in the first 6\u00a0h of the study, and urine composition was assessed at predefined timepoints. The study group presented the exponential (rather than linear) pattern of relationship between UNa\n                    <jats:sup>+<\/jats:sup>\n                    and 6-h urine volume, whereas relationship between eGFR and 6-h urine volume was linear (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.61,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). The relationship between UNa\n                    <jats:sup>+<\/jats:sup>\n                    and all other analyzed indices of urine dilution, including the change from baseline in urine creatinine concentration, urine osmolarity, and urine osmolarity corrected for urine sodium, also exhibited an exponential relationship. Patients who were chronically exposed to furosemide demonstrated a significantly lower urine dilution (1.78 [1.18\u20133.54] vs 11.58 [3.9\u201317.88];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) in comparison to na\u00efve individuals. In conclusion, it should be noted that in AHF higher UNa\n                    <jats:sup>+<\/jats:sup>\n                    is associated with disproportionally higher urine dilution, and patients na\u00efve to furosemide have significantly greater ability to dilute urine when compare to chronic furosemide users.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-51744-x","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T08:02:06Z","timestamp":1705478526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Spot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure"],"prefix":"10.1038","volume":"14","author":[{"given":"Mateusz","family":"Guzik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gracjan","family":"Iwanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zymli\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Marciniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Biegus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"51744_CR1","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/ejhf.890","volume":"19","author":"O Chioncel","year":"2017","unstructured":"Chioncel, O. et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur. J. Heart Fail. 19, 1242\u20131254 (2017).","journal-title":"Eur. J. Heart Fail."},{"key":"51744_CR2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368 (2021).","journal-title":"Eur. Heart J."},{"key":"51744_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","volume":"21","author":"W Mullens","year":"2019","unstructured":"Mullens, W. et al. The use of diuretics in heart failure with congestion\u2014a position statement from the heart failure association of the European society of cardiology. Eur. J. Heart Fail 21, 137\u2013155 (2019).","journal-title":"Eur. J. Heart Fail"},{"key":"51744_CR4","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/ejhf.1428","volume":"21","author":"J Biegus","year":"2019","unstructured":"Biegus, J. et al. Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. Eur. J. Heart Fail 21, 624\u2013633 (2019).","journal-title":"Eur. J. Heart Fail"},{"key":"51744_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ejhf.2053","volume":"23","author":"J Biegus","year":"2021","unstructured":"Biegus, J. et al. Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients. Eur. J. Heart Fail 23, 729\u2013739 (2021).","journal-title":"Eur. J. Heart Fail"},{"key":"51744_CR6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijcard.2017.08.053","volume":"254","author":"S Honda","year":"2018","unstructured":"Honda, S. et al. Long-term prognostic significance of urinary sodium concentration in patients with acute heart failure. Int. J. Cardiol. 254, 189\u2013194 (2018).","journal-title":"Int. J. Cardiol."},{"key":"51744_CR7","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/eurheartj\/ehx035","volume":"38","author":"W Mullens","year":"2017","unstructured":"Mullens, W., Verbrugge, F. H., Nijst, P. & Tang, W. H. W. Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. Eur. Heart J. 38, 1872\u20131882 (2017).","journal-title":"Eur. Heart J."},{"key":"51744_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1161\/HYPERTENSIONAHA.120.15205","volume":"76","author":"CS Wilcox","year":"2020","unstructured":"Wilcox, C. S., Testani, J. M. & Pitt, B. Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure. Hypertension 76, 1045\u20131054 (2020).","journal-title":"Hypertension"},{"key":"51744_CR9","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1152\/physrev.2000.80.3.1107","volume":"80","author":"M Wyss","year":"2000","unstructured":"Wyss, M. & Kaddurah-Daouk, R. Creatine and creatinine metabolism. Physiol. Rev. 80, 1107\u20131213 (2000).","journal-title":"Physiol. Rev."},{"key":"51744_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2019.10.025","volume":"72","author":"K Kashani","year":"2020","unstructured":"Kashani, K., Rosner, M. H. & Ostermann, M. Creatinine: From physiology to clinical application. Eur. J. Intern. Med. 72, 9\u201314 (2020).","journal-title":"Eur. J. Intern. Med."},{"key":"51744_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2852","author":"J Biegus","year":"2023","unstructured":"Biegus, J. et al. The blunted loop diuretic response in acute heart failure is driven by reduced tubular responsiveness rather than insufficient tubular delivery. The role of furosemide urine excretion on diuretic and natriuretic response in acute heart failure. Eur. J. Heart Fail https:\/\/doi.org\/10.1002\/ejhf.2852 (2023).","journal-title":"Eur. J. Heart Fail"},{"key":"51744_CR12","doi-asserted-by":"publisher","first-page":"F374","DOI":"10.1152\/ajprenal.1985.248.3.F374","volume":"248","author":"B Kaissling","year":"1985","unstructured":"Kaissling, B., Bachmann, S. & Kriz, W. Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment. Am. J. Physiol. Renal Physiol. 248, F374\u2013F381 (1985).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"51744_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1159\/000082314","volume":"24","author":"G-H Kim","year":"2004","unstructured":"Kim, G.-H. Long-term adaptation of renal ion transporters to chronic diuretic treatment. Am. J. Nephrol. 24, 595\u2013605 (2004).","journal-title":"Am. J. Nephrol."},{"key":"51744_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. New Eng. J. Med. 384, 117\u2013128 (2021).","journal-title":"New Eng. J. Med."},{"key":"51744_CR15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors, A. A. et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat. Med. 28, 568\u2013574 (2022).","journal-title":"Nat. Med."},{"key":"51744_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","volume":"44","author":"J Biegus","year":"2023","unstructured":"Biegus, J. et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur. Heart J. 44, 41\u201350 (2023).","journal-title":"Eur. Heart J."},{"key":"51744_CR17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/ejhf.1713","volume":"22","author":"K Damman","year":"2020","unstructured":"Damman, K. et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur. J. Heart Fail 22, 713\u2013722 (2020).","journal-title":"Eur. J. Heart Fail"},{"key":"51744_CR18","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam, M. A. Effects of oral Tolvaptan in patients hospitalized for worsening heart failure<Subtitle>the Everest outcome trial<\/subtitle>. JAMA 297, 1319 (2007).","journal-title":"JAMA"},{"key":"51744_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/AC.70.3.3080630","volume":"70","author":"HF Verbrugge","year":"2015","unstructured":"Verbrugge, H. F. et al. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. Acta Cardiol. 70, 265\u2013273 (2015).","journal-title":"Acta Cardiol."},{"key":"51744_CR20","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1002\/ehf2.13372","volume":"8","author":"J Biegus","year":"2021","unstructured":"Biegus, J. et al. Spot urine sodium in acute heart failure: differences in prognostic value on admission and discharge. ESC Heart Fail 8, 2597\u20132602 (2021).","journal-title":"ESC Heart Fail"}],"updated-by":[{"DOI":"10.1038\/s41598-024-59807-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51744-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51744-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51744-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T06:25:22Z","timestamp":1713421522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51744-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51744"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-51744-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,17]]},"assertion":[{"value":"26 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-024-59807-9","URL":"https:\/\/doi.org\/10.1038\/s41598-024-59807-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.F. was supported by the National Heart, Lung, and Blood Institute (NHLBI) (K23HL151744), the American Heart Association (20IPA35310955), Doris Duke, Bayer, Bodyport, and Verily. He receives consulting fees from Abbott, Alio Health, Alleviant, Audicor, AxonTherapies, Bayer, Bodyguide, Bodyport, Boston Scientific, Cadence, Coridea, CVRx, Daxor, Deerfield Catalyst, Edwards LifeSciences, EKO, Feldschuh Foundation, Fire1, Gradient, Impulse Dynamics, Intershunt, Medtronic, NIMedical, NXT Biomedical, Pharmacosmos, PreHealth, ReCor, Shifamed, Splendo, Sumacor, SyMap, Verily, Vironix, Viscardia, Zoll. P.P. reports personal fees from Boehringer Ingelheim, AstraZeneca, Servier, Bristol Myers Squibb, Amgen, Novartis, Merck, Pfizer, Berlin Chemie, and grants and personal fees from Vifor Pharma. M.G., G.I., R.Z., D.M., J.B. have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1494"}}